Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
BioNTech, the German drug company best known for its experimental messenger RNA therapies, has raised $325 million in series B financing to move more of its drug candidates to the clinic and build up its manufacturing capacity. The fast-growing firm had raised about $500 million over the past 2 years from private investors and pharmaceutical collaborators. BioNTech says it needs the money to further build and test its experimental cancer immunotherapies, including antibodies, cell therapies, mRNA therapies, and small molecules.
This article has been sent to the following recipient: